The Department of Public Health published the COVID-19 Therapeutics Information Brief (1.25.22) including the following updates:
- Bamlanvimab/Etesevimab and REGEN-COV no longer authorized for use by FDA
- Allocations for mAbs, PrEP and Antivirals
- Disposal of extra doses of Nirmatrelvir from blister packs for patients with low eGFR
- COVID-19 treatment guidelines when there are logistical or supply constraints
- Patient prioritization for outpatient Anti-SARS-CoV-2 therapies with supply constraints
- FDA expands use of REMDESIVIR
- COVID-19 treatment guidelines for Evusheld
The next Therapeutics Information Brief will be February 2.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.